Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Gets Canadian OK for MRSA/SA Test

NEW YORK (GenomeWeb News) – Cepheid has received marketing clearance in Canada for its Xpert MRSA/SA Blood Culture test for rapid detection of methicillin-resistant Staphylococcus aureus and Staphylococcus aureus in blood culture bottles showing gram-positive cocci.

The test processes positive blood culture specimens to determine if a patient's blood is infected with MRSA or SA, which Cepheid said are frequent causes of sepsis in hospitalized patients. Such a test can enable physicians to "quickly de-escalate from broad-spectrum antibiotic treatment to a more effective targeted therapy, thus reducing risk of resistance and improving patient outcomes," the firm said in a statement today.

According to Cepheid, more than 250,000 Canadian patients experience infected surgical wounds, blood infections, and antibiotic-resistant organisms while in the hospital each year.

Cepheid noted that the Xpert MRSA/SA Blood Culture test is the firm's sixth test to receive a license from Health Canada.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.